Calendar
event
Ex dividend date
21 Feb 2025
event_available
Last Dividend Payment
24 Mar 2025
About AstraZeneca PLC ADR
Ticker
info
AZN
Trading on
info
NASDAQ
ISIN
info
US0463531089
Industry
info
Drug Manufacturers - General
Sector
info
Healthcare
CEO
info
Pascal Claude Roland Soriot D.V.M., M.B.A.
Headquarters
info
1 Francis Crick Avenue, Cambridge, undefined, United Kingdom, CB2 0AA
Employees
info
94,300
Website
info
astrazeneca.com
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Metrics
BasicAdvanced
Market cap
info
$210B
P/E ratio
info
30.16
EPS
info
$2.25
Dividend Yield
info
2.28%
Beta
info
0.25
Forward P/E ratio
info
15.38
EBIDTA
info
$17.6B
Ex dividend date
info
2025-02-21
Price & volume
Market cap
info
$210B
Average daily volume
info
6.8M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$3.10
Dividend yield
info
2.28%
Forward dividend per share
info
$1.55
Forward dividend yield
info
2.28%
Payout ratio
info
43.44%
Valuation
P/E ratio
info
30.16
Forward P/E
info
15.38
PEG ratio
info
0.97
Trailing P/E
info
30.16
Price to sales
info
3.89
Price to book
info
6.19
Earnings
EPS
info
$2.25
EPS estimate (current quarter)
info
$1.07
EPS estimate (next quarter)
info
$1.03
EBITDA
info
$17.6B
Revenues (TTM)
info
$54.1B
Revenues per share (TTM)
info
$2.90
Technicals
Beta
info
0.25
52-week High
info
$86.46
52-week Low
info
$61.24
50-day moving average
info
$73.04
200-day moving average
info
$73.88
Short ratio
info
1.9
Short %
info
0.34%
Management effectiveness
ROE (TTM)
info
17.59%
ROA (TTM)
info
7.88%
Profit margin
info
13.01%
Gross profit margin
info
$44.4B
Operating margin
info
22.72%
Growth
Quarterly earnings growth (YoY)
info
56.70%
Quarterly revenue growth (YoY)
info
23.80%
Share stats
Outstanding Shares
info
3.1B
Float
info
1.54B
Insiders %
info
0.00%
Institutions %
info
17.50%
Analyst Insights & forecasts
info

91% Buy

9% Hold

0% Sell

Based on information from 11 analysts.

Average price target

info
$84.79
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$1.03
$1.22
15.57%
Q1 • 24Beat
$0.99
$1.20
17.50%
Q2 • 24Beat
$0.46
$1.04
56.02%
Q3 • 24Beat
$1.05
$1.04
0.84%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$13.6B
$1.43B
10.53%
Q3 • 24
$14.9B
$1.5B
10.07%
Q4 • 24
9.78%
4.97%
4.38%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$105B
$64.1B
61.11%
Q3 • 24
$104B
$63.2B
60.71%
Q4 • 24
0.85%
1.49%
0.65%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$3.38B
$-1.51B
$-4.13B
$2.03B
Q3 • 24
$2.91B
$-1.18B
$-671M
$1.95B
Q4 • 24
14.07%
21.99%
83.76%
3.60%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a AstraZeneca PLC ADR share?
Collapse

AstraZeneca PLC ADR shares are currently traded for undefined per share.

How many shares does AstraZeneca PLC ADR have?
Collapse

AstraZeneca PLC ADR currently has 3.1B shares.

Does AstraZeneca PLC ADR pay dividends?
Collapse

Yes, AstraZeneca PLC ADR does pay dividends.

What is AstraZeneca PLC ADR 52 week high?
Collapse

AstraZeneca PLC ADR 52 week high is $86.46.

What is AstraZeneca PLC ADR 52 week low?
Collapse

AstraZeneca PLC ADR 52 week low is $61.24.

What is the 200-day moving average of AstraZeneca PLC ADR?
Collapse

AstraZeneca PLC ADR 200-day moving average is $73.88.

Who is AstraZeneca PLC ADR CEO?
Collapse

The CEO of AstraZeneca PLC ADR is Pascal Claude Roland Soriot D.V.M., M.B.A..

How many employees AstraZeneca PLC ADR has?
Collapse

AstraZeneca PLC ADR has 94,300 employees.

What is the market cap of AstraZeneca PLC ADR?
Collapse

The market cap of AstraZeneca PLC ADR is $210B.

What is the P/E of AstraZeneca PLC ADR?
Collapse

The current P/E of AstraZeneca PLC ADR is 30.16.

What is the EPS of AstraZeneca PLC ADR?
Collapse

The EPS of AstraZeneca PLC ADR is $2.25.

What is the PEG Ratio of AstraZeneca PLC ADR?
Collapse

The PEG Ratio of AstraZeneca PLC ADR is 0.97.

What do analysts say about AstraZeneca PLC ADR?
Collapse

According to the analysts AstraZeneca PLC ADR is considered a buy.